FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200319621> ?p ?o ?g. }

• W4200319621 abstract "Carbapenemase-producing, carbapenem-resistant Pseudomonas aeruginosa (CP-CRPA) is a global challenge. However, detection efforts can be laborious because numerous mechanisms produce carbapenem resistance. A minimum inhibitory concentration-based algorithm (imipenem- or meropenem-resistant plus ceftazidime-nonsusceptible plus cefepime-nonsusceptible) was proposed to identify the isolates most likely to harbor a carbapenemase; however, prospective validation in geographies displaying genotypic diversity and varied carbapenemase prevalence is warranted.CRPA isolates were collected during the Enhancing Rational Antimicrobials for P. aeruginosa (ERACE-PA) global surveillance program from 17 sites in 12 countries. Isolates underwent susceptibility testing following local standards to ceftazidime, cefepime, and ceftolozane/tazobactam. Isolates underwent initial phenotypic carbapenemase screening followed by molecular testing if positive. The primary algorithm criteria were applied, and results were compared with phenotypic carbapenemase results to assess the performance of the algorithm. A secondary criterion, the algorithm criterion or imipenem- or meropenem-resistant plus ceftolozane/tazobactam-nonsusceptible, was assessed.A total of 807 CRPA were assessed, and 464 isolates met the algorithm criteria described above. Overall, testing was reduced by 43% compared with testing all CRPA. Carbapenemase-positive isolates missed by the algorithm were largely driven by Guiana extended spectrum (GES). Addition of the criterion of imipenem- or meropenem-resistant plus ceftolozane/tazobactam-nonsusceptible decreased the number of CP-CRPA missed by the algorithm (21 vs 40 isolates, respectively), reducing number of isolates tested by 39%.Application of the initial algorithm (imipenem- or meropenem-resistant plus ceftazidime-nonsusceptible plus cefepime-nonsusceptible) performed well in a global cohort, with 33% phenotypically carbapenemase-positive isolates. The addition of imipenem- or meropenem-resistant plus ceftolozane/tazobactam-nonsusceptible reduced the number of phenotypically carbapenemase-positive isolates missed and may be useful in areas with a prominence of GES." @default.
• W4200319621 created "2021-12-31" @default.
• W4200319621 creator A5001141136 @default.
• W4200319621 creator A5009642231 @default.
• W4200319621 creator A5012938560 @default.
• W4200319621 creator A5023479710 @default.
• W4200319621 creator A5026024562 @default.
• W4200319621 creator A5028200056 @default.
• W4200319621 creator A5031044365 @default.
• W4200319621 creator A5036220332 @default.
• W4200319621 creator A5040836317 @default.
• W4200319621 creator A5050014117 @default.
• W4200319621 creator A5053449231 @default.
• W4200319621 creator A5054640183 @default.
• W4200319621 creator A5058683198 @default.
• W4200319621 creator A5062302144 @default.
• W4200319621 creator A5071676972 @default.
• W4200319621 creator A5075014516 @default.
• W4200319621 creator A5076324401 @default.
• W4200319621 creator A5090740872 @default.
• W4200319621 creator A5091643420 @default.
• W4200319621 creator A9999999999 @default.
• W4200319621 date "2021-12-13" @default.
• W4200319621 modified "2023-10-15" @default.
• W4200319621 title "Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant<i>Pseudomonas aeruginosa</i>Using the ERACE-PA Global Surveillance Program" @default.
• W4200319621 cites W2075287054 @default.
• W4200319621 cites W2293828825 @default.
• W4200319621 cites W2796258527 @default.
• W4200319621 cites W2889354016 @default.
• W4200319621 cites W2986744786 @default.
• W4200319621 cites W3014918727 @default.
• W4200319621 cites W3016673927 @default.
• W4200319621 cites W3094445652 @default.
• W4200319621 cites W3097456628 @default.
• W4200319621 cites W3118311975 @default.
• W4200319621 cites W3118524433 @default.
• W4200319621 cites W3122827512 @default.
• W4200319621 cites W3136894677 @default.
• W4200319621 cites W3183647471 @default.
• W4200319621 cites W3184556518 @default.
• W4200319621 doi "https://doi.org/10.1093/ofid/ofab617" @default.
• W4200319621 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35106312" @default.
• W4200319621 hasPublicationYear "2021" @default.
• W4200319621 type Work @default.
• W4200319621 citedByCount "3" @default.
• W4200319621 countsByYear W42003196212022 @default.
• W4200319621 countsByYear W42003196212023 @default.
• W4200319621 crossrefType "journal-article" @default.
• W4200319621 hasAuthorship W4200319621A5001141136 @default.
• W4200319621 hasAuthorship W4200319621A5009642231 @default.
• W4200319621 hasAuthorship W4200319621A5012938560 @default.
• W4200319621 hasAuthorship W4200319621A5023479710 @default.
• W4200319621 hasAuthorship W4200319621A5026024562 @default.
• W4200319621 hasAuthorship W4200319621A5028200056 @default.
• W4200319621 hasAuthorship W4200319621A5031044365 @default.
• W4200319621 hasAuthorship W4200319621A5036220332 @default.
• W4200319621 hasAuthorship W4200319621A5040836317 @default.
• W4200319621 hasAuthorship W4200319621A5050014117 @default.
• W4200319621 hasAuthorship W4200319621A5053449231 @default.
• W4200319621 hasAuthorship W4200319621A5054640183 @default.
• W4200319621 hasAuthorship W4200319621A5058683198 @default.
• W4200319621 hasAuthorship W4200319621A5062302144 @default.
• W4200319621 hasAuthorship W4200319621A5071676972 @default.
• W4200319621 hasAuthorship W4200319621A5075014516 @default.
• W4200319621 hasAuthorship W4200319621A5076324401 @default.
• W4200319621 hasAuthorship W4200319621A5090740872 @default.
• W4200319621 hasAuthorship W4200319621A5091643420 @default.
• W4200319621 hasAuthorship W4200319621A9999999999 @default.
• W4200319621 hasBestOaLocation W42003196211 @default.
• W4200319621 hasConcept C2776685102 @default.
• W4200319621 hasConcept C2776968632 @default.
• W4200319621 hasConcept C2777050379 @default.
• W4200319621 hasConcept C2777637488 @default.
• W4200319621 hasConcept C2778266534 @default.
• W4200319621 hasConcept C2779375183 @default.
• W4200319621 hasConcept C2779631663 @default.
• W4200319621 hasConcept C501593827 @default.
• W4200319621 hasConcept C523546767 @default.
• W4200319621 hasConcept C54355233 @default.
• W4200319621 hasConcept C71924100 @default.
• W4200319621 hasConcept C86803240 @default.
• W4200319621 hasConcept C89423630 @default.
• W4200319621 hasConcept C94665300 @default.
• W4200319621 hasConceptScore W4200319621C2776685102 @default.
• W4200319621 hasConceptScore W4200319621C2776968632 @default.
• W4200319621 hasConceptScore W4200319621C2777050379 @default.
• W4200319621 hasConceptScore W4200319621C2777637488 @default.
• W4200319621 hasConceptScore W4200319621C2778266534 @default.
• W4200319621 hasConceptScore W4200319621C2779375183 @default.
• W4200319621 hasConceptScore W4200319621C2779631663 @default.
• W4200319621 hasConceptScore W4200319621C501593827 @default.
• W4200319621 hasConceptScore W4200319621C523546767 @default.
• W4200319621 hasConceptScore W4200319621C54355233 @default.
• W4200319621 hasConceptScore W4200319621C71924100 @default.
• W4200319621 hasConceptScore W4200319621C86803240 @default.
• W4200319621 hasConceptScore W4200319621C89423630 @default.
• W4200319621 hasConceptScore W4200319621C94665300 @default.
• W4200319621 hasIssue "2" @default.
• W4200319621 hasLocation W42003196211 @default.
• W4200319621 hasLocation W42003196212 @default.

• next